AustinPx is a contract development and manufacturing organization (CDMO) that provides preclinical through Phase II formulation and process development, as well as GMP manufacturing of oral dosage forms. The company specializes in bioavailability enhancement, utilizing KinetiSol™ Technology.

AustinPx

AustinPx | 2,979 followers on LinkedIn. Client-Centric CDMO helping developers realize the full potential of their drug candidates. | AustinPx™, Pharmaceutics and Manufacturing, was founded to help developers realize the full potential of their drug candidates. There are many obstacles to bringing a drug to market, including poor bioavailability and accelerated timelines. That’s where we come in.

Tim Scott

Vice President of Operations at AustinPx

Justin Keen

Chief Scientific Officer at AustinPx

Dave A. Miller, Ph.D.

Controller at Austin PX, Pharmaceutics and Manufacturing

Jay Meyer

Today, on Veterans Day, we honor the people who support our country through military service, both those who serve directly and those who stand by them. At AustinPx , we’re inspired by the courage, dedication, and sacrifices of our team members and their loved ones who contribute to protecting our freedom including Jonathon Den Beste , Daniel Ellenberger, Amy Kimbro , Jacquelyn Stamatedes , and Tong Ma . Thank you to all veterans and their families for your invaluable commitment. #VeteransDay #HonoringService #AustinPx

Happy National STEM Day! Today, we recognize the educators and organizations inspiring young minds to explore Science, Technology, Engineering, and Math. At AustinPx, we’re proud to support STEM by sparking curiosity in the next generation through events like our Bring Your Child to Work Day, where future scientists dive into hands-on experiments. As we tackle health and environmental challenges, advances in STEM give us hope for a brighter future. Here’s to those who inspire tomorrow’s innovators, we’re excited to see what they achieve! #STEM #NationalSTEMDay #Leadership

We’re excited to highlight a recent article from AustinPx CSO, Dave A. Miller, Ph.D. that discusses the importance of formulation development in designing a simple, stable, and bioavailable dosage form for complex moleules. Access to advanced technology and expertise can be the key to ensuring performance, scalability and sustainability upon commercialization. #formulationdevelopment #GMPmanufacturing #PharmaInnovation #AustinPx To learn more, read the full article here: https://lnkd.in/g3vCTSan

Don’t forget to mark your calendars! We are hosting our next regional happy hour event with Lubrizol Life Science on Wednesday, Nov. 6th, from 4-7 p.m. in Research Triangle Park, NC. #HappyHour #PharmaNetworking #ResearchTrianglePark RSVP here: https://lnkd.in/gcR-Enkd

We are excited to share our recent webinar on overcoming the challenges of scaling up Amorphous Solid Dispersions (ASDs) with Justin Keen , Senior VP of Operations at AustinPx , and TJ Higley, CEO at Microsize (Micronization, Particle Size Engineering, Pharmaceutical Development) . They shared best practices for tech transfer and explored improvements in scalability using next-generation technologies like KinetiSol™. If you’re interested in learning more about improving the bioavailability of poorly soluble drugs and the next generation of amorphous dispersion technology, this webinar is for you! Watch here on YouTube: https://lnkd.in/gqHhr_vF Listen here on our website: https://lnkd.in/g5pYQsJB #PharmaInnovation #KinetiSol #ASD #TechTransfer #PharmaManufacturing #SustainableTech #DrugDevelopment #Bioavailability

We are excited to announce another upcoming regional happy hour event in Research Triangle Park, NC! We are hosting Suds & Solubility Happy Hour on Wednesday, Nov. 6th from 4-7pm, with Lubrizol Life Science, where all the suds are on us. We look forward to seeing you there! RSVP here: https://lnkd.in/gcR-Enkd #HappyHour #PharmaNetworking #ResearchTrianglePark

We are incredibly honored and excited to announce that AustinPx has been named the winner of the Accelerating Innovation Award at the 2024 CPHI Pharma Awards for our work on Kinetisol! This honor reflects our dedication to contributing to a healthier planet while delivering innovative drug solutions, and it strengthens our resolve to improve bioavailability and sustainability through Kinetisol Technology. At the ceremony in Milan, Italy, our CBO, Elizabeth Hickman , accepted the award and promised to continue our innovation journey to help shape the future of pharmaceutical development. #CPHI2024 #AcceleratingInnovation #Kinetisol #PharmaceuticalManufacturing #PharmaInnovation #CDMO To read more, access our full press release here: https://lnkd.in/gxdCWSVy

As the excitement builds for AAPS PharmSci 360, AustinPx is looking forward to diving deeper into the emerging trends in drug formulation, targeted therapeutics, and leveraging AI in drug development. We know that now, more than ever, accelerating the drug development timeline while maintaining quality is critical to advancing patient care. If you’re interested in learning how we can help you navigate the challenges of formulation and bioavailability enhancement, let's connect during the event. Schedule a meeting with us to discuss how we can collaborate to advance your drug development goals. Visit: www.austinpx.com/AAPS-2024 #AAPS2024 #PharmaInnovation #DrugDevelopment #CDMO #Bioavailability #PharmaceuticalScience

Happy National Chemistry Week! At AustinPx , we know that behind every breakthrough in drug development, there’s a deep understanding of chemistry. From enhancing the bioavailability of complex compounds to innovating sustainable manufacturing practices, chemistry is at the core of everything we do. As we celebrate the role of chemistry in improving lives, we want to acknowledge the brilliant scientists who are shaping the future of pharmaceuticals. Here’s to pushing the boundaries of what’s possible through chemistry—today and every day. Let’s keep the innovation going! #NationalChemistryWeek #Pharmaceuticals #Innovation #ChemistryInAction #SustainableScience #DrugDevelopment

I am incredibly honored to share that AustinPx has won in the Accelerating Innovation category at the CPHI Pharma Awards, thanks to the groundbreaking work we've done with KinetiSol! This recognition reflects the impact KinetiSol has had in transforming drug manufacturing, particularly in enhancing bioavailability while also significantly reducing our environmental footprint. By eliminating the need for harmful solvents, KinetiSol stands at the intersection of pharmaceutical innovation and sustainability, offering a greener alternative without compromising on efficiency or quality. It’s an exciting time for us, and I’m eager to continue pushing boundaries and collaborating with others who are equally passionate about improving drug development processes. #CPHI2024 #AcceleratingInnovation #Sustainability #KinetiSol #PharmaceuticalManufacturing #Bioavailability #PharmaInnovation #AustinPx #CDMO

msh id	COM:AUSTINPX
symbol	-
name	AustinPx
homepage url	https://www.austinpx.com
country	US
sector	Healthcare & Health Services
industry	Pharmaceuticals
market	PRIVATE
employee count	-
crunchbase url	https://www.crunchbase.com/organization/dispersol-technologies
linkedin url	https://www.linkedin.com/company/austin-pharmaceutics
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

AUST

COM:AUSTINPX

AustinPx

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-